— Akamai Technologies, Inc. (NASDAQ: AKAM) reported third-quarter 2019 earnings of $1.10 per share, vs. $1 per share expected.
— Total revenue grew 6% to $710 million, vs. $701.3 million expected.
— Security product revenue jumped 29% YoY.
— On track to achieve 30% operating margin in 2020: CEO Tom Leighton.
— AKAM shares were down 0.36% immediately following the announcement.
Most Popular
Context Therapeutics: Another clinical-stage oncology research firm to go public soon
The US primary markets seem to be having a record-breaking start to the year, with over $171 billion raised in the first half of 2021 compared to $168 billion for
Biogen (BIIB) Stock: Does FDA nod for Aduhelm offer a buying opportunity?
The pharmaceutical industry has been witnessing hectic activity for some time, with most drug makers either channelizing their resources for vaccine development or engaging in COVID care programs. Biotechnology giant
IPO News: Monte Rosa Therapeutics will go public this week, here are a few things to know
Biotechnology company Monte Rosa Therapeutics is slated to go public this week. In a pandemic-ridden world, this industry is expanding at a healthy pace. The global biotechnology market is estimated
